117 related articles for article (PubMed ID: 21827981)
1. Impact of Histone Modifications and Their Therapeutic Targeting in Hematological Malignancies.
Markouli M; Strepkos D; Piperi C
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362442
[TBL] [Abstract][Full Text] [Related]
2. 2-O-Methylmagnolol, a Magnolol Derivative, Suppresses Hepatocellular Carcinoma Progression via Inhibiting Class I Histone Deacetylase Expression.
Chen CY; Fang JY; Chen CC; Chuang WY; Leu YL; Ueng SH; Wei LS; Cheng SF; Hsueh C; Wang TH
Front Oncol; 2020; 10():1319. PubMed ID: 32850418
[No Abstract] [Full Text] [Related]
3. Proteasome inhibitor MG-132 enhances histone deacetylase inhibitor SAHA-induced cell death of chronic myeloid leukemia cells by an ROS-mediated mechanism and downregulation of the Bcr-Abl fusion protein.
Zhou W; Zhu W; Ma L; Xiao F; Qian W
Oncol Lett; 2015 Nov; 10(5):2899-2904. PubMed ID: 26722260
[TBL] [Abstract][Full Text] [Related]
4. Polyamine-based small molecule epigenetic modulators.
Sharma SK; Hazeldine S; Crowley ML; Hanson A; Beattie R; Varghese S; Senanayake TM; Hirata A; Hirata F; Huang Y; Wu Y; Steinbergs N; Murray-Stewart T; Bytheway I; Casero RA; Woster PM
Medchemcomm; 2012; 3(1):14-21. PubMed ID: 23293738
[TBL] [Abstract][Full Text] [Related]
5. Romidepsin for the treatment of non-Hodgkin's lymphoma.
Yazbeck VY; Grant S
Expert Opin Investig Drugs; 2015; 24(7):965-79. PubMed ID: 25936363
[TBL] [Abstract][Full Text] [Related]
6. Romidepsin: a novel histone deacetylase inhibitor for cancer.
Bertino EM; Otterson GA
Expert Opin Investig Drugs; 2011 Aug; 20(8):1151-8. PubMed ID: 21699444
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors in the treatment of hematological malignancies.
Petrella A; Fontanella B; Carratù A; Bizzarro V; Rodriquez M; Parente L
Mini Rev Med Chem; 2011 Jun; 11(6):519-27. PubMed ID: 21561404
[TBL] [Abstract][Full Text] [Related]
8. [Histone deacetylase inhibitors in the treatment of hematological malignancies].
Lemal R; Ravinet A; Moluçon-Chabrot C; Bay JO; Guièze R
Bull Cancer; 2011 Aug; 98(8):867-78. PubMed ID: 21827981
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylases and epigenetic therapies of hematological malignancies.
Mercurio C; Minucci S; Pelicci PG
Pharmacol Res; 2010 Jul; 62(1):18-34. PubMed ID: 20219679
[TBL] [Abstract][Full Text] [Related]
10. Histone deacetylase inhibitor givinostat: the small-molecule with promising activity against therapeutically challenging haematological malignancies.
Ganai SA
J Chemother; 2016 Aug; 28(4):247-54. PubMed ID: 27121910
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
